[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 1987

Influence of Long-term Androgen Therapy on Growth: An Analysis of 18 Cases of Aplastic Anemia in Children

Author Affiliations

The Cooperative Study Group of Aplastic and Refractory Anemias Department of Nuclear Medicine Hôpital Saint-Louis 1, Ave Claude-Vellefaux 75010 Paris, France

Am J Dis Child. 1987;141(7):718-719. doi:10.1001/archpedi.1987.04460070020006

Sir.—Androgen therapy enhances both maturation and growth. Its longterm administration at high dosages has raised concern among pediatricians, who fear dwarfism in their patients, with all its psychological consequences.

Androgen therapy is, in the short1 and long2 terms, an efficient treatment in a large proportion of aplastic anemias, whether they are of toxic or primitive origin. The Cooperative Study Group of Aplastic and Refractory Anemias has over a long period of time studied the growth of 18 children who were cured (or whose conditions were at least notably improved) by high-dose androgen therapy. The results of this study show that the height attained at adulthood does not statistically differ from that of a reference population and that, subsequently, no side effect on growth should be feared when choosing a therapy potentially important to a child's survival.

Patients and Methods.—In the cooperative study group, 84 children